Suppr超能文献

瑞典随机乳腺钼靶筛查试验:对其与乳腺癌相关的超额死亡率影响的分析。

The Swedish randomised mammography screening trials: analysis of their effect on the breast cancer related excess mortality.

作者信息

Larsson L G, Nyström L, Wall S, Rutqvist L, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L

机构信息

Department of Oncology, University Hospital, Umeå, Sweden.

出版信息

J Med Screen. 1996;3(3):129-32. doi: 10.1177/096914139600300305.

Abstract

OBJECTIVE

To apply an indirect method for estimation of the breast cancer related excess mortality in the Swedish randomised mammography screening trials.

SETTING

Randomised trials on mammography screening have, in Sweden, been performed in the counties of Kopparberg (W) and Ostergötland (E), the so called WE study, and in the three largest cities in Sweden, Stockholm (southern part), Gothenburg, and Malmö. An overview of the trials was presented in the Lancet in 1993 and included 156,911 women in the invited group and 125,866 in the control group.

METHODS

The excess mortality in the breast cancer subgroups was estimated by indirect standardisation using official national cause of death statistics according to Statistics Sweden as a reference.

RESULTS

The estimated reduction of the breast cancer related mortality was 24% for the whole group (40-74 years at randomisation). The corresponding figures for the age groups 40-49, 50-59, and 60-69 years were 6%, 28%, and 34% respectively.

CONCLUSION

The results are very similar to those presented earlier based on the traditional comparison of the breast cancer mortality in the invited and in the control group. This analysis further strengthens previous reports on a beneficial effect of mammography screening, which is especially pronounced in the age group 50-69.

摘要

目的

应用间接方法估算瑞典随机乳腺钼靶筛查试验中与乳腺癌相关的超额死亡率。

背景

在瑞典,已在耶夫勒堡县(W)和东约特兰省(E)开展了乳腺钼靶筛查随机试验,即所谓的WE研究,同时也在瑞典的三个最大城市——斯德哥尔摩(南部)、哥德堡和马尔默进行了试验。1993年《柳叶刀》杂志发表了这些试验的综述,受邀组有156,911名女性,对照组有125,866名女性。

方法

以瑞典统计局的官方全国死因统计数据作为参考,采用间接标准化方法估算乳腺癌亚组中的超额死亡率。

结果

整个组(随机分组时年龄为40 - 74岁)与乳腺癌相关的死亡率估计降低了24%。40 - 49岁、50 - 59岁和60 - 69岁年龄组的相应数字分别为6%、28%和34%。

结论

这些结果与早期基于受邀组和对照组乳腺癌死亡率的传统比较得出的结果非常相似。该分析进一步强化了先前关于乳腺钼靶筛查有益效果的报道,这种效果在50 - 69岁年龄组中尤为明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验